CONTENTS:
- ITP & PLATELET DISORDERS RESEARCH & TREATMENTS:
- Avatrombopag, a New TPO Agent, Demonstrates Superiority to Placebo in Phase 3 Trial
- Predicting Bleeding Risk in Pediatric ITP
- Decitabine Restores Immune Tolerance
- Second Line ITP Treatments Improve Quality of Life and Fatigue in Children
- Results from Phase 2 Trial of Rozanolixizumab, an Anti-FcRn Antibody
- Long-Term Platelet Response to Fostamatinib in Adults with ITP